Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial

NCT00249158 is registered in ClinicalTrials.gov with Janssen-Cilag Pty Ltd as lead sponsor.

NCT NCT00249158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00249158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial
Lead sponsor
Janssen-Cilag Pty Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 31, 1998
Completion date
February 28, 2001
Enrollment
344 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, dementia, vascular dementia